INTERVIEW: Mylan set to rev up Indian ops but wants policy stability
This article was originally published in Scrip
Executive Summary
If plans outlined by the multinational generic company's president are anything to go by, Mylan appears set for a major expansion in India, boosted by its recent acquisition of local firm Agila Specialties, although it is maintaining a generally cautious stance over policy-related uncertainties in the country.
You may also be interested in...
Baxter Injects $625m In ‘Foundational Asset’ Claris
Baxter has snapped up India’s Claris Injectables, accelerating efforts to become a global leader in generic injectables. The deal also puts the spotlight back on the significant M&A appetite in the niche injectables segment and the scarcity premiums that such assets can command.
Chinese Stamp On Indian Pharma; All Eyes On Regulatory Flow
The Fosun group led by its billionaire chair Guo Guangchang has snapped up the injectables firm Gland for around $1.26bn, the first mega Chinese buy in the Indian pharmaceutical space. The deal opens up many potential collaborative opportunities, though it remains to be seen how smoothly it sails through in the Indian regulatory maze.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.